Literature DB >> 9223843

Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies.

N Hagen1, R Swanson.   

Abstract

While occasional myoclonic jerks are prevalent in cancer patients receiving opioids, severe myoclonic jerks and seizures due to opioids are uncommon. In this retrospective case series, we describe five cancer patients with refractory cancer pain and severe neuroexcitatory toxicity associated with extremely high-dose opioid therapy to characterize better the syndrome, its treatment, and its outcome. Two patients died following seizures, but three patients recovered following prompt treatment with parenteral midazolam infusions and rotation to alternative opioids. Possible mechanisms and treatment options for this potentially lethal clinical syndrome are reviewed. The authors conclude that severe multifocal myoclonus and seizures associated with extremely high-dose opioid therapy are life-threatening, and respond to parenteral midazolam infusion, rotation to alternative opioids, and aggressive supportive care.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9223843     DOI: 10.1016/S0885-3924(97)00001-8

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  4 in total

Review 1.  OROS hydromorphone prolonged release: a review of its use in the management of chronic, moderate to severe pain.

Authors:  Natalie J Carter; Gillian M Keating
Journal:  CNS Drugs       Date:  2010-04       Impact factor: 5.749

Review 2.  Morphine-3-Glucuronide, Physiology and Behavior.

Authors:  Florian Gabel; Volodya Hovhannisyan; Abdel-Karim Berkati; Yannick Goumon
Journal:  Front Mol Neurosci       Date:  2022-05-12       Impact factor: 6.261

3.  Opioid-induced myoclonus and hyperalgesia following a short course of low-dose oral morphine.

Authors:  Owen Bleddyn Woodward; Sangeeta Naraen; Akriti Naraen
Journal:  Br J Pain       Date:  2016-08-22

Review 4.  Drug-associated delirium in cancer patients.

Authors:  Augusto Caraceni
Journal:  EJC Suppl       Date:  2013-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.